Power wheelchair — group 2 denied as not FDA-approved for this use by UnitedHealthcare?

Under UnitedHealthcare's Commercial medical policy, mobility devices including manual wheelchairs, electric wheelchairs, transfer chairs, scooters/power-operated vehicles (POV), canes, and walkers are a covered health care service when medically necessary. The policy aligns with CMS LCD L33789, which establishes that the beneficiary must have a mobility limitation that significantly impairs his/her ability to participate in one or more mobility-related activities of daily living (MRADLs) such as toileting, feeding, dressing, grooming, and bathing in customary locations in the home — a limitation that prevents the beneficiary from accomplishing an MRADL entirely, places the beneficiary at heightened risk of morbidity or mortality, or prevents completing an MRADL within a reasonable time frame ; additionally, the mobility limitation cannot be sufficiently and safely resolved by an appropriately fitted cane or walker, and the beneficiary does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. Use of a power wheelchair must significantly improve the beneficiary's ability to participate in MRADLs and the beneficiary will use it in the home (for severe cognitive/physical impairments, participation in MRADLs may require caregiver assistance), and the beneficiary has not expressed an unwillingness to use a power wheelchair in the home. For a Group 2 standard PWC, a Group 2 PWC (K0820, K0821, K0822, K0823, K0824, K0825, K0826, K0827, K0828, K0829) is covered if all of the coverage criteria (a)-(e) for a PWC are met and the wheelchair is appropriate for the beneficiary's weight. For a Group 2 Single Power Option PWC, all coverage criteria (a)-(e) must be met, plus the beneficiary meets coverage criteria for a power tilt or recline seating system OR requires a drive control interface other than a hand or chin-operated standard proportional joystick (examples include head control, sip and puff, switch control) , and a specialty evaluation must be performed by a licensed/certified medical professional (PT, OT, or practitioner with rehab wheelchair training) with no financial relationship with the supplier, and the wheelchair must be provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) with direct, in-person involvement in the wheelchair selection. DME has a reasonable useful lifetime (RUL) of 5 years , and payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary.

- **Document MRADL impact in detail**: Provide a clinician note specifying which MRADLs (toileting, feeding, dressing, grooming, bathing) the patient cannot complete or completes only with heightened morbidity/mortality risk, directly mapping to the LCD L33789 definition of a qualifying mobility limitation . - **Stepwise rule-out of lesser devices**: Submit PT/OT documentation explaining why a cane, walker, and optimally-configured manual wheelchair each fail — addressing strength, endurance, ROM, coordination, pain, or upper-extremity deformity per the LCD's enumerated upper-extremity assessment factors (strength, endurance, range of motion, coordination, pain, deformity or absence of one or both upper extremities) . - **Provide compliant face-to-face and WOPD**: Attach the dated face-to-face mobility examination note and the signed Standard Written Order before delivery; cite Final Rule 1713's requirement of a face-to-face encounter and Written Order Prior to Delivery as satisfied. - **Include RESNA ATP and independent specialty evaluation**: For Group 2 Single Power Option chairs, include both the ATP credential attestation and the independent PT/OT specialty evaluation, satisfying the requirement that a licensed PT/OT with no financial relationship to the supplier perform the specialty evaluation and that a RESNA-certified ATP have direct involvement in wheelchair selection . - **Demonstrate in-home use**: Document home assessment showing adequate access between rooms and maneuvering space, and explicitly state the device will be used in the home to meet the requirement that the beneficiary's home provides adequate access and that the power wheelchair will significantly improve the beneficiary's ability to participate in MRADLs in the home . - **Justify Group 2 over Group 1**: If denied as needing only a Group 1, document the patient's weight against capacity limits or, for Single Power Option, the medical necessity of power tilt/recline (e.g., pressure ulcer risk, inability to perform a functional weight shift) or alternative drive control interface per LCD L33789 Group 2 Single Power Option criteria including need for non-standard drive control such as head control, sip and puff, or switch control . - **Replacement vs. repair**: For replacement requests, document the 5-year RUL and that the existing chair cannot be repaired or no longer meets the patient's needs, citing the 5-year reasonable useful lifetime standard and UHC's allowance for upgrades when the member's condition changes (e.g., impaired function necessitates an upgrade to a power wheelchair from a manual one) .

## Why UHC denied your Group 2 power wheelchair as "not FDA-approved"

A "not FDA-approved" denial for a Group 2 PWC (HCPCS K0820–K0829) is almost always a miscoded NCD/LCD failure, not a true device-clearance dispute. Power wheelchairs are 510(k)-cleared Class II devices regulated under 21 CFR §890.3860 — every K0820–K0829 base on UHC's fee schedule already carries a PDAC HCPCS Coding Verification letter confirming FDA clearance. When UHC's DME utilization arm (operated through Optum/naviHealth post-acute review for MA, and Optum DME for Commercial) returns "not FDA-approved," they are almost always conflating (1) a missing PDAC code verification, (2) an off-label seating component (power tilt/recline, alternative drive control), or (3) a configuration that exceeds CMS LCD L33789's investigational threshold under the Mobility Devices, Options, and Accessories policy.

The Mobility Devices MP cross-walks directly to L33789, so UHC cannot impose a coverage standard stricter than the LCD without violating 45 CFR §156.122 (ACA EHB continuity) and, for MA enrollees, 42 CFR §422.566. Under Pinto v. Aetna Life Ins. Co. (10th Cir. 2014), an ERISA plan asserting "experimental/investigational" carries the burden of producing the specific evidentiary record — UHC must identify which component lacks FDA clearance and cite the FDA database entry it relied on. A blanket "not FDA-approved" line is facially deficient under 29 CFR §2560.503-1(g)(1)(v)(A), which requires the specific scientific or clinical judgment underlying the denial.

## How to attack it

Pull the denial letter and identify whether UHC denied the base code (K0820–K0829) or an option/accessory (E1002 power tilt, E1007 combined tilt/recline, E2310 electronic interface, E2312 mini-proportional joystick). Bases are categorically FDA-cleared; options may be the real target. Then build a three-layer appeal:

1. Coding layer — attach the PDAC Product Classification List entry showing the exact base and each option carries an active HCPCS verification. PDAC verification is functionally a coverage-side proxy for FDA clearance under CMS DMEPOS rules. 2. Clinical layer — submit the LCD L33789 element-by-element checklist: face-to-face mobility exam within 6 months, ATP-involved specialty evaluation by an independent PT/OT (no financial relationship with the supplier), home assessment confirming maneuverability, and MRADL-specific functional deficits. For Single Power Option chairs, document the alternative drive interface justification. 3. Regulatory layer — cite 42 CFR §405.1062 (LCDs bind contractors but cannot be applied more restrictively by MAOs) and demand the reviewer's specialty under 29 CFR §2560.503-1(h)(3)(iii) — a same-specialty physiatrist or PM&R reviewer, not a general medical director.

File the appeal through the UHC Provider Portal → DME Reconsideration queue (Commercial) or UHC Medicare Advantage Part C Appeal with expedited 72-hour designation if mobility loss is causing imminent MRADL harm. Optum is the back-end reviewer; address the letter to Optum DME Clinical Review, not generic UHC appeals.

## Tactical tip

Request the complete claim file under 29 CFR §2560.503-1(h)(2)(iii) before drafting the appeal — including the specific FDA database query UHC ran. Nine times out of ten there is no query, which converts the denial into a procedural violation and shifts the burden under Pinto. Pair with a same-day complaint to your state DOI (Commercial) or 1-800-MEDICARE QIC referral (MA) to anchor the appeal timeline.